Skye Bioscience, Inc. (SKYE)
| Market Cap | 88.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.65M |
| Shares Out | 30.98M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,682,175 |
| Open | 2.370 |
| Previous Close | 2.160 |
| Day's Range | 2.310 - 3.180 |
| 52-Week Range | 1.140 - 8.440 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | 16.60 (+478.4%) |
| Earnings Date | Aug 8, 2025 |
About SKYE
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Die... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price forecast is $16.6, which is an increase of 478.40% from the latest price.
News
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other m...
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other m...
Skye Bioscience to Participate in Upcoming Investment Conferences
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other me...
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
Proprietary formulation technology being applied to potentially enhance properties of nimacimab Proprietary formulation technology being applied to potentially enhance properties of nimacimab
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health...
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and...
Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE) Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President & Chief Executive...
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-...
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other me...
Skye Bioscience to Participate in May Investment and Medical Conferences
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
Weight loss drug stocks like Novo Nordisk have dropped significantly lately. This presents potential value opportunities in a market projected to grow to $105 billion by 2035. Skye Bioscience's nimaci...
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
Skye Bioscience, Inc. SKYE stock is trading higher on Tuesday with a strong session volume of 18.49 million compared to the average volume of 196.131k, as per data from Benzinga Pro.
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates superi...
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and ot...
Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Bernie Hertel - Head of Investor Relations Punit Dhillon - President and Chief Exec...
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other ...
Skye Bioscience to Present at TD Cowen Health Care Conference
SAN DIEGO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity...
Skye Bioscience Announces Participation in February Conferences
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and oth...
MoneyShow's Best Investment Ideas For 2025: Part 8
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur...
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and oth...
Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy
Skye Bioscience's Nimacimab shows promising Phase 1 safety data and is in Phase 2 trials, potentially revolutionizing obesity treatment with minimal neuropsychiatric side effects. Nimacimab's large-mo...
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic healt...
Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript
Skye Bioscience, Inc. (NASDAQ:SKYE) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Bernie Hertel - Head, Investor Relations Punit Dhillon - President and CEO Kaitly...
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways fo...
Skye Bioscience to Announce Third Quarter 2024 Results
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic healt...